HWM
LRMR icon

HB Wealth Management’s Larimar Therapeutics LRMR Stock Holding History

HB Wealth Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49K Buy
+16,078
New +$63.8K ﹤0.01% 1681

Other funds holding LRMR

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
NLP
Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return

HB Wealth Management's LRMR Position: Q2 2026 in Review

HB Wealth Management opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 16,078 shares worth $49K. The stake represents ﹤0.01% of the portfolio and ranks #1681 among its holdings.

26 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • HB Wealth Management held 16,078 shares of Larimar Therapeutics worth $49K as of Q2 2026.
  • Larimar Therapeutics was a new HB Wealth Management position in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1681 holding.
  • 26 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.